Carl Zeiss X-Ray Microscopy vs. Sigray: X-Ray Imaging Patent Verdict
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Carl Zeiss X-Ray Microscopy, Inc. v. Sigray, Inc. |
| Numéro de dossier | 5:21-cv-01129 (N.D. Cal.) |
| Tribunal | Tribunal fédéral de première instance, district nord de Californie |
| Durée | Feb 2021 – Jan 2026 4 years 11 months |
| Résultat | Plaintiff Win — $785K Damages |
| Brevets en cause | |
| Produits incriminés | Sigray TriLambda NanoXRM Microscope, Prisma, Eclipse |
Aperçu du dossier
Les parties
⚖️ Demandeur
X-ray microscopy division of the globally recognized Carl Zeiss group, a leader in optical and imaging systems with a significant patent portfolio in x-ray optics and nano-scale imaging.
🛡️ Défendeur
California-based startup specializing in advanced x-ray technology, including laboratory-scale x-ray sources and microscopy systems competing in the nano-resolution imaging market.
Les brevets en cause
This landmark case involved two U.S. patents protecting foundational x-ray microscopy apparatus and detection technology, critical to high-resolution imaging in semiconductor inspection, materials science, and life sciences research.
- • U.S. Patent No. 7,057,187 — covering x-ray microscopy apparatus and detection technology. Key claims 1–6, 8–12, and 17 were found infringed.
- • U.S. Patent No. 7,400,704 — directed to x-ray imaging systems and optical configurations. Key claims 7, 9–15 were found infringed.
Developing a similar x-ray imaging product?
Check if your product design might infringe these or related patents before launch.
Le verdict et l'analyse juridique
Outcome Summary
The jury delivered a split verdict, finding Sigray liable for infringing Carl Zeiss’s x-ray microscopy patents and awarding $785,000 in damages as a reasonable royalty. This outcome highlights the significant value of legacy patent portfolios in specialized technology markets.
Patent Damages Awarded
| Produit | Patent(s) | Damages |
|---|---|---|
| TriLambda | ‘187 Patent | $170,000 |
| Prisma | ‘187 & ‘704 Patents | $421,000 |
| Eclipse | ‘704 Patent | $194,000 |
| Total | $785,000 |
Principales questions juridiques
All infringement findings rested on literal infringement, establishing that Sigray’s accused products embodied each element of the asserted claims without relying on the doctrine of equivalents. This is a robust finding for the plaintiff, reinforcing clear claim scope.
Critically, the jury found Sigray’s infringement was not willful, protecting Sigray from potentially triple damages under 35 U.S.C. § 284. This demonstrates the effectiveness of a strong defense against willfulness, likely by presenting reasonable beliefs in non-infringement or invalidity.
Parallel trade secret claims resulted in a **partial defense victory** for Sigray. While some alleged trade secrets were found to qualify as such, the jury found no misappropriation of any of the 15 alleged trade secrets. This underscores the high evidentiary bar for proving both the existence of a trade secret and its improper use.
Freedom to Operate (FTO) Analysis in X-Ray Imaging
This case highlights critical IP risks in the scientific instrumentation and x-ray microscopy market. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Voir tous les brevets liés à ce domaine technologique
- See which companies are most active in x-ray imaging patents
- Comprendre les schémas d'interprétation des revendications pour les systèmes optiques
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- AI identifies potentially blocking patents in x-ray optics
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Precision X-ray microscopy apparatus
2 Patents Infringed
Foundational x-ray optical systems
No Willful Infringement
Avoided enhanced damages
✅ Points clés à retenir
Literal infringement findings across multiple claims and products significantly strengthen a plaintiff’s position.
Rechercher la jurisprudence connexe →A successful defense against willfulness can protect defendants from enhanced damages, emphasizing the importance of building a contemporaneous good-faith record.
Explorer les précédents →Trade secret claims, while adding complexity, require meeting distinct evidentiary standards for both existence and misappropriation.
Learn more about trade secret litigation →Multi-patent, multi-product assertion strategies maximize royalty exposure and negotiating leverage in specialized technology markets.
Analyze patent portfolio strategy →Reasonable royalty damages in niche instrumentation markets provide useful licensing benchmarks for future negotiations or expert damages analyses.
Benchmark licensing rates →Foire aux questions
The case involved U.S. Patent No. 7,057,187 and U.S. Patent No. 7,400,704, both directed to x-ray microscopy imaging systems and optical configurations.
The jury awarded $785,000 in total reasonable royalties across three accused Sigray products: TriLambda ($170,000), Prisma ($421,000), and Eclipse ($194,000).
The jury found no misappropriation of any alleged trade secrets — meaning even those qualifying as trade secrets were not improperly acquired or used by Sigray, defeating the claim on its merits.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER — Case No. 5:21-cv-01129, U.S. District Court, Northern District of California
- USPTO Patent Center — U.S. Patent No. 7,057,187
- USPTO Patent Center — U.S. Patent No. 7,400,704
- Cornell Legal Information Institute — 35 U.S.C. § 284 (Damages)
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.